Leung Chung Wai. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2006. / Includes bibliographical references (leaves 142-146). / Abstracts in English and Chinese. / ABSTRACT (ENGISH) --- p.iii / ABSTRACT (CHINESS) --- p.v / ACHKNOWLEDGEMENTS --- p.vii / TABLE OF CONTENTS --- p.viii / Chapter CHAPTER 1 --- Introduction and Background / Chapter 1.1 --- Introduction of Platinum Drugs --- p.1 / Chapter 1.2 --- Mechanism of Action of Cisplatin --- p.3 / Chapter 1.3 --- Structure-Activity Relationships of the Platinum Drug 、 --- p.4 / Chapter 1.4 --- QS AR Parameters --- p.9 / Chapter 1.4.1 --- Chemical Hardness: Descriptor of Chemical Reactivity --- p.9 / Chapter 1.4.2 --- Possible Reaction Pathway of Platinum Drugs --- p.12 / Chapter 1.4.2.1 --- Proposed DNA Binding Pathway of Platinum Drugs --- p.13 / Chapter 1.4.2.1.1 --- Hydrolysis Pathway --- p.13 / Chapter 1.4.2.1.2 --- DNA Binding Pathway Involving the S-containing Biomolecules (Methionine Pathways) --- p.16 / Chapter 1.4.2.1.3 --- Conclusion --- p.21 / Chapter 1.5 --- Thesis Scope --- p.22 / Chapter CHAPTER 2 --- Theory and Methodology / Chapter 2.1 --- Introduction --- p.24 / Chapter 2.2 --- Density Functional Theory (DFT) --- p.24 / Chapter 2.2.1 --- Kohn-Sham Theorem --- p.25 / Chapter 2.2.2 --- Exchange-Correlation Energy Functional --- p.27 / Chapter 2.3 --- Basis Set --- p.27 / Chapter 2.3.1 --- Relativistic Effective Core Potential --- p.27 / Chapter 2.3.2 --- Double-Zeta --- p.28 / Chapter 2.3.3 --- Polarized Basis Set --- p.29 / Chapter 2.4 --- Solvation Model --- p.30 / Chapter 2.4.1 --- Continuum Model --- p.30 / Chapter 2.4.1.1 --- Simple Solvation Model --- p.31 / Chapter 2.4.1.1.1 --- Electrostatic Component --- p.31 / Chapter 2.4.1.1.2 --- Dispersion-Repulsion Interaction --- p.33 / Chapter 2.4.1.1.3 --- Cavitatoin Energy --- p.35 / Chapter 2.4.1.2 --- Polarized Continuum Model --- p.36 / Chapter 2.5 --- Methodology --- p.39 / Chapter 2.5.1 --- Calculation of DFT Global Reactivity Index --- p.39 / Chapter 2.5.1.1 --- Calculation for the Reaction Intermediates --- p.41 / Chapter 2.5.2 --- Calculation of the Reaction Pathways --- p.42 / Chapter CHAPTER 3 --- Results and Discussion / Chapter 3.1 --- Introduction --- p.49 / Chapter 3.2 --- Optimized Structure against Experimental Geometry --- p.49 / Chapter 3.3 --- Kohn-Sham Orbitals --- p.54 / Chapter 3.3.1 --- Location of the HOMO and LUMO --- p.55 / Chapter 3.4 --- Results of the DFT Reactivity Parameter --- p.57 / Chapter 3.5 --- Chemical Structure of the Drugs in the QSAR --- p.64 / Chapter 3.6 --- QSAR Analysis --- p.67 / Chapter 3.6.1 --- The Overall QSAR Plot of the Platinum Drugs --- p.68 / Chapter 3.6.1.1 --- Empirical Applicability of the QSAR on the Platinum(IV) Drugs --- p.70 / Chapter 3.6.1.2 --- Detail QASR Study According to the Type of Platinum Drug --- p.71 / Chapter 3.6.1.2.1 --- QSAR Study of the non-“trans-DACH´ح Platinum Drugs --- p.72 / Chapter 3.6.1.2.1.1 --- "QSAR Equation of the non-""trαns-DACH"" Platinum Drugs" --- p.75 / Chapter 3.6.1.2.2 --- QSAR Analysis for the Pt-trαns-DACH Drugs --- p.77 / Chapter 3.6.1.2.2.1 --- "QSAR Study of trans-S,S-DACH Platinum Drugs" --- p.79 / Chapter 3.6.1.2.2.2 --- "QSAR Study of trans-R,R-DACH Platinum Drugs" --- p.80 / Chapter 3.6.1.3 --- Summary --- p.81 / Chapter 3.7 --- QSAR Study of the Important Intermediates Using Chemical Hardness --- p.82 / Chapter 3.7.1 --- Optimized Structure for the Intermediates --- p.84 / Chapter 3.7.2 --- QSAR of the Dichloride Pt-Drugs Using Chemical Hardness of Parent Compounds --- p.90 / Chapter 3.7.3 --- QSAR of the Dichloride Pt-Drugs Using Chemical Hardness of Hydrolysis Intermediates --- p.91 / Chapter 3.7.4 --- QSAR of the Dichloride Pt-Drugs Using Chemical Hardness of Cyclic-Methionine Intermediates --- p.93 / Chapter 3.7.5 --- Conclusion --- p.95 / Chapter CHAPTER 4 --- Results and Discussion / Chapter 4.1 --- Introduction --- p.96 / Chapter 4.2 --- Study Scheme --- p.97 / Chapter 4.3 --- Optimized Structures --- p.98 / Chapter 4.4 --- Comments on the Reliability of the Calculation Model --- p.103 / Chapter 4.4.1 --- Reaction Profile in the Gas Phase --- p.104 / Chapter 4.4.2 --- Reaction Profiles Using Simple Solvation Model --- p.105 / Chapter 4.4.2.1 --- Defects of the Simple Solvation Model --- p.107 / Chapter 4.4.3 --- Reaction Profile Using PCM-UAHF Solvation Model --- p.109 / Chapter 4.4.3.1 --- Selection of the Reaction Parameters for the QSAR Study --- p.112 / Chapter 4.5 --- QSAR Study of Platinum Drugs Using the Reaction Parameters (AG and ΔG+) --- p.121 / Chapter 4.5.1 --- QSAR Analysis Using ΔG+(hydrolysis) --- p.121 / Chapter 4.5.2 --- QSAR Analysis Using ΔG(hydrolysis) --- p.123 / Chapter 4.5.3 --- QSAR Analysis Using ΔG+(guanine) --- p.125 / Chapter 4.5.4 --- QSAR Analysis Using ΔG(guanine) --- p.127 / Chapter 4.5.5 --- Further investigation of the Bidentate Pt-drugs DNA Binding --- p.129 / Chapter 4.5.5.1 --- Calculation Model --- p.129 / Chapter 4.5.5.2 --- Bidentate Pt-Drugs Reactions --- p.130 / Chapter 4.5.5.3 --- Selection of the Calculated Model for the QSAR Study --- p.133 / Chapter 4.5.5.4 --- QSAR Analysis Using ΔG+(guanine) for the Platinum Drugs with Bidentate Caboxylate Ligands --- p.136 / Chapter 4.5.5.5 --- QSAR Analysis Using ΔG(guanine) for the Platinum Drugs with Bidentate Carboxylate Ligands --- p.137 / Chapter 4.5.6 --- Conclusion --- p.138 / Chapter CHAPTER 5 --- Conclusion Remarks and Future Works / Chapter 5.1 --- Conclusion --- p.140 / Chapter 5.2 --- Future Works --- p.141 / REFERENCES --- p.142